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Immune-based cancer therapies have demonstrated bene-
fit in multiple clinical trials. The interest in using recombi-
nant bacteria as vaccine vectors for active cancer
immunotherapy derives in part from their ability to stimu-
late multiple innate immune pathways and, at the same
time, to effectively deliver antigen for presentation to the
adaptive immune system. We have developed a vaccine
platform based on LADD Listeria monocytogenes (Lm)
in which two virulence genes (actA and inlB) have been
deleted from the Lm chromosome which leads to a
1,000-fold attenuation without loss of its ability to induce
potent innate and adaptive cellular immunity. Our lead
therapeutic, CRS-207, engineered to express the tumor-
associated antigen mesothelin, has been tested in 3 clinical
studies to date. In a Phase 1 study in 17 patients with
advanced cancers that express mesothelin, CRS-207
appeared to be well-tolerated at several dose levels
and induced mesothelin-specific CD8+ T cell immunity
(Le D Clin. Cancer Res 2012). CRS-207 is currently being
tested at a dose level of 1×109 CFU in clinical trials with
patients with metastatic pancreatic ductal adenocarcinoma
(PDA) and in frontline unresectable malignant pleural
mesothelioma (MPM). Importantly, no serious adverse
events (AEs) related to CRS-207 have been reported in
these studies. In the study with metastatic PDA patients,
the most common AEs related to administration of the
combination immunotherapy treatment (immunomodula-
tory doses of cyclophosphamide, GVAX pancreas vaccine
and CRS-207) were nausea, vomiting, chills, fatigue, fever
and injection site reactions (related to intradermal GVAX
injections). No accumulative toxicities in subsequent
administrations have been observed. Encouragingly, in this
randomized, Phase 2 study, PDA patients receiving the
immunotherapy combination of cyclophosphamide,
GVAX pancreas vaccine and CRS-207 survived signifi-
cantly longer than subjects receiving cyclophosphamide
and GVAX pancreas vaccine alone. The study was stopped
for efficacy at the interim analysis based on recommenda-
tion by the independent data monitoring committee.
Additionally, in the Phase 1b study in MPM patients
where CRS-207 is sequenced with chemotherapy, encoura-
ging anti-tumor activity has been observed, with two
minor and two partial responses (PRs) in the first
4 patients. Based on these studies, it appears that CRS-207
can be safely administered intravenously to patients with
late-stage metastatic disease at doses up to 1×109 CFU,
vaccination can induce the intended immune response
and may contribute to extended survival in advanced
cancer patients.
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